The 2026 Program

Selected startups pitch their vision for the next generation of health and longevity.

An informal opening gathering for speakers, attendees and partners.

Reserve a 20-minute group session in NGL Live (up to 14 guests): 8:10 or 8:30 AM, or 12:30, 12:50 or 1:30 PM. At all other times, walk-ins are welcome.

Matcha is served after the experience.

Discussion with physicians from distinct paths, philosophies and clinical models that led them to longevity medicine, and where their approaches converge or differ.

A rapid discussion separating established physiology from persistent myths while examining how science, clinical practice and policy are reshaping the hormone conversation across the healthspan.

Leading longevity clinicians and scientists evaluate the same complex patient through the interconnected lenses of brain, heart, gut and hormonal health. Each participant must prioritize risk, determine what matters first and defend a treatment strategy.

A live conversation on what the biology of aging tells us today, which mechanisms matter most, and where intervention may realistically alter trajectory.

A focused discussion on what is scientifically credible, clinically actionable and ready for responsible translation in regenerative and cellular medicine.

A discussion of how Japan and other global markets are balancing scientific evidence, patient access, regulatory flexibility and clinical responsibility in regenerative medicine.

How communication among the nervous, immune and endocrine systems may influence inflammation, resilience and the trajectory of aging.

A discussion of traditional medical systems, contemplative practices, consciousness and psychedelics, and what remains meaningful when examined through the lens of modern science.

Closing Day 1 with a look toward what comes next: how Hims & Hers, a global company now serving longevity care around the world, is poised to become the first global company to do so, and what that means for the field.

Need a place to unwind? After dinner each night, the team will be at the Hilton Osaka bar. Come say hello.

Reserve your place in NGL Live (30 guests per session).

As the science of aging becomes increasingly actionable, the challenge moves beyond whether we can influence healthspan to what happens when we translate those discoveries across populations, healthcare systems and societies.

Friday lunchtime only. Reserve a 20-minute group session in NGL Live (up to 14 guests): 12:15, 12:35 or 12:55 PM. At other times, walk-ins are welcome.

Matcha is served after the experience.

By 2050, more than two billion people will be over 60, with most living in low- and middle-income countries. Participants are challenged to design a minimum viable longevity system for a resource-constrained health system: what stays, what goes, what should be measured and where limited resources should be deployed first.

An interactive examination of how AI may reshape medicine, from interpreting increasingly complex biological data to changing the physician-patient encounter itself.

Are aging biomarkers now reliable, responsive and clinically useful enough to guide prevention? An examination of what these tools can measure today, how they respond to intervention and where their limitations remain.

Life insurance has traditionally priced the risk of illness and death. Could biological-age testing allow insurers to become active partners in prevention? This session explores how epigenetic testing is being applied, what incentives it could create and what implementation might look like in practice.

Could Japan combine aging biomarkers, preventive care and insurance incentives into a scalable longevity model? A focused discussion of what could be implemented, who would pay and what infrastructure and partnerships would be required.

A telehealth platform, consumer health brand and diagnostics company are each racing to become the patient’s front door for longevity. The strategic question is whether they compete to own the entire relationship or interoperate and divide the value, and where durable value ultimately accrues as longevity scales.

Need a place to unwind? After dinner each night, the team will be at the Hilton Osaka bar. Come say hello.

Dr. Maier lays out the fundamentals: what geroscience is, the hallmarks of aging, chronological vs. biological age, and how longevity medicine differs from conventional sick care. She covers how biomarkers of aging are measured and used to guide individualized prevention strategies, and traces the translational bridge from research to clinical practice.

Dr. Ishido walks through how autophagy is actually measured in humans today, which intervention strategies — dietary, supplement, pharmacological — are furthest along and most clinically actionable right now, and what it took to move from a university lab to a real product pipeline.

Dr. Fransén has years of experience analyzing the longevity biotech market and provides a clinician-scientist’s lens on which drugs are best positioned for clinical impact.

Dr. Molina’s work sets the standardized protocols, multi-omics analysis, and functional tests used to measure functional age-reversal in muscle, cognitive, and immune function in the $101M XPRIZE Healthspan. Together, they shift the conversation from “what’s the next blockbuster longevity drug” to “how would we know it worked.”

Dr. Grady walks through how to decode an individual’s gut microbiome, connecting it to current science on GI, metabolic, autoimmune, neurological, and longevity-related outcomes. He makes the case for the gut as an actionable diagnostic layer, and for AI as the tool that lets you apply insights with precision for personalized prevention.

Elise Lilliehöök highlights evidence that social relationships are one of the strongest, most ancient predictors of a long life. She makes the case for treating loneliness and social disconnection as a measurable, addressable longevity risk factor, and shows how technology can be designed to create deeper human connection rather than substitute for it.

How can virtual care make preventive health services easier to reach and use? This session examines the patient journey from first contact to ongoing care, focusing on access, clinical trust, clinical effectiveness, and the practical challenges of delivering a consistent experience at scale.

Tim Doyle walks through what it takes to scale GLP-1 telehealth access in Japan’s insurance-driven, clinical guideline-gated system. He makes the case for the emerging “GLP-1 moment” in Japan and what builders and clinicians should watch as the landscape continues to evolve and open new opportunities.

Popa walks through the operator’s view of what it takes to invest in and open a longevity clinic: infrastructure costs, unit economics, and the practical steps and logistics from idea to first patient.

Dr. Kennedy closes Day 1 by walking through the development of biological age clocks, the different types, and speaking candidly about where clocks are ready for the clinic and where the field still needs more evidence.

Julie Baron picks up directly from there with LinAge2, showing where it translates in the real world and exactly how a biological-age score becomes a concrete, personalized action plan.

Shah brings the regulation and access lens to hormone therapy. Drawing on the large-scale evidence linking testosterone deficiency to measurable disease, he makes the case for where hormone therapy fits in longevity strategies, where regulation has lagged behind the science, what access looks like in practice today, and where the opportunity lies for anyone building in this space.

Dr. Comite shows what it looks like to treat each individual based on their unique biological signature and experience. She walks through how hormones and other key biomarkers are measured, interpreted in the context of the individual, and targeted with precision interventions to guide disease prevention and reversal. Attendees leave with a practical framework for personalizing longevity care in women and men, and a view of where precision medicine is heading.

Dr. Husain covers cardiovascular-specific aging patterns, their systemic ripple effects, and the integrative cardiology strategies he uses to protect heart health before disease appears.

Dr. Molina frames his work identifying measurable, blood-based signatures of physiological and cognitive resilience, and how tracking changes over time could guide early intervention strategies that protect brain health and extend healthspan.

Dr. Bosnak explains how compassionate AI can sense the emotion beneath words, through tone, facial expression and body language, and respond with presence and empathy. He makes the case for using it to offer connection and care when a human can’t be there.

Dr. Foong presents the evidence for declining estrogen and other sex hormones as measurable drivers of cardiovascular disease, osteoporosis, metabolic disease and cognitive decline, and makes the case that midlife, and menopause in particular, is a pivotal window for prevention rather than quality-of-life care alone. Drawing on more than 25 years in family medicine, she shows where HRT fits in a longevity strategy, how it can be integrated into everyday primary care alongside lifestyle medicine, and what it means for women’s healthspan.

Why NGL chose Japan: the global longevity imperative, and why Japan’s combination of the world’s most advanced aging demographics, a sophisticated functional-food and regenerative-medicine framework, and a clear two-track regulatory pathway positions it as a central node in the Asia-Pacific longevity market, arguably the earliest, highest-signal one globally.

Wang brings a regional view from TimePie, one of China’s leading longevity organizations, mapping the forces shaping the market: the clinics and operators scaling now, the regulatory terrain they’re navigating, and what’s accelerating adoption, from strong government backing to deep cultural investment in prevention and healthy aging. The talk makes the case for why the region’s trajectory is a leading indicator for where global longevity medicine is headed.